Jaguar Health Q4 2019 Earnings Report
Key Takeaways
Jaguar Health reported strong Mytesi sales growth in 2019 and is planning to initiate three clinical trials in the second half of 2020, subject to additional financing.
Mytesi net sales and gross sales grew 38% and 44%, respectively, in 2019 compared to 2018.
The company aims to forge a regional, ex-US business development deal to bring in non-dilutive dollars.
Plans to complete the roll-out of new patient support program for Mytesi.
Napo Pharmaceuticals will receive additional preclinical services from the National Institute of Allergy and Infectious Diseases (“NIAID”) to support development of lechlemer.
Jaguar Health
Jaguar Health
Forward Guidance
Jaguar Health anticipates a transformative year in 2020 with key goals including business development deals, patient support program roll-out, and clinical trial initiations.
Positive Outlook
- 2020 has the potential to be a transformative year for the Company
- Forging an ex-US business development deal to bring in non-dilutive dollars to support efforts to move key potential Mytesi pipeline indications into development, commercialization, and access outside the U.S.
- Completing the roll-out of new patient support program for Mytesi
- Planning to initiate three clinical trials in the second half of 2020
- Napo will receive additional preclinical services from NIAID to support development of lechlemer
Challenges Ahead
- Additional financing is needed to initiate three clinical trials in the second half of 2020.